LP 9
Alternative Names: LP 9 extract; LP-9Latest Information Update: 01 May 2007
At a glance
- Originator Credere Corporation
- Developer Credere Corporation; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 May 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 22 Jan 2002 Preclinical development for Cancer in USA (unspecified route)